Skip to main content

Table 1 Demographics and clinical characteristics of Behçet’s disease (BD) patients

From: Metabolomic alterations associated with Behçet’s disease

Parameter Value
Age (years), mean ± SD 35.83 ± 11.96
Age at BD diagnosis (years), median (range) 28.5 (17–60)
Disease duration (months), median (range) 120(13–379)
BDCAF, median (range) 10 (3–33)
Clinical features of BD
 Oral ulcer 24 (100%)
 Genital ulcer 17 (70.8%)
 Skin lesions 16 (66.7%)
 Ocular lesions 8 (33.3%)
 Vascular involvement 7 (29.2%)
 Pathergy reaction 5 (20.8%)
 Gastrointestinal involvement 3 (12.5%)
 Neurologic involvement 1 (4.2%)
Erythrocyte sedimentation rate (mm/h), median (range) 15.5 (2–76)
C-reactive protein (mg/L), median (range) 9.62 (0.56–53.1)
Treatment-naive 7 (29.2%)
Current medications
 Glucocorticoid 15 (62.5%)
 Thalidomide 13 (54.2%)
 Cyclophosphamide 11 (45.8%)
 Salazosulfapyridine 3 (12.5%)
 Cyclosporine A 2 (8.3%)
 Methotrexate 2(8.3%)
 Azathioprine 1 (4.2%)
 Etanercept 1 (4.2%)
  1. Values are shown as n (%) unless otherwise indicated
  2. BDCAF Behçet’s Disease Current Activity Form